SpeeDx Pty. Ltd. announced the incorporation of a US-based subsidiary company, SpeeDx Inc. The US base will support current clinical trial activity for ResistancePlus™ MG, in preparation for an expected US launch in 2018.
“We have always had the goal of bringing ResistancePlus MG to the US market”, said Colin Denver, CEO, “local offices and staff will allow us to more easily navigate the FDA approval process and keep us on track for our product launch next year.”
Read the full press release here